Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases

Yue-Jiao Lan,1,2 Napoleon Bellua Sam,3 Ming-Han Cheng,1 Hai-Feng Pan,4,5 Jian Gao1 1Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2The Second Affiliated Hospital, Dalian Medical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lan YJ, Sam NB, Cheng MH, Pan HF, Gao J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	pgrn tnf-α tnfr immune-mediated diseases therapeutic Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/94ca2290387d4d6ab0fb7434aed4b006
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94ca2290387d4d6ab0fb7434aed4b006
record_format	dspace
spelling	oai:doaj.org-article:94ca2290387d4d6ab0fb7434aed4b0062021-12-05T18:27:45ZProgranulin as a Potential Therapeutic Target in Immune-Mediated Diseases1178-7031https://doaj.org/article/94ca2290387d4d6ab0fb7434aed4b0062021-12-01T00:00:00Zhttps://www.dovepress.com/progranulin-as-a-potential-therapeutic-target-in-immune-mediated-disea-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Yue-Jiao Lan,1,2 Napoleon Bellua Sam,3 Ming-Han Cheng,1 Hai-Feng Pan,4,5 Jian Gao1 1Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 3Department of Medical Research and Innovation, School of Medicine, University for Development Studies, Tamale, Ghana; 4Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, People’s Republic of China; 5Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, People’s Republic of ChinaCorrespondence: Jian GaoPediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, People’s Republic of ChinaEmail gaojian@scmc.com.cn; gaojianayfy@163.comHai-Feng PanDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, People’s Republic of ChinaEmail panhaifeng@ahmu.edu.cnAbstract: Progranulin (PGRN), a secretory glycoprotein consisting of 593 amino acid residues, is a key actor and regulator of multiple system functions such as innate immune response and inflammation, as well as tissue regeneration. Recently, there is emerging evidence that PGRN is protective in the development of a variety of immune-mediated diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) by regulating signaling pathways known to be critical for immunology, particularly the tumor necrosis factor alpha/TNF receptor (TNF-α/TNFR) signaling pathway. Whereas, the role of PGRN in psoriasis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) is controversial. This review summarizes the immunological functions of PGRN and its role in the pathogenesis of several immune-mediated diseases, in order to provide new ideas for developing therapeutic strategies for these diseases.Keywords: PGRN, TNF-α, TNFR, immune-mediated diseases, therapeuticLan YJSam NBCheng MHPan HFGao JDove Medical Pressarticlepgrntnf-αtnfrimmune-mediated diseasestherapeuticPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 6543-6556 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pgrn tnf-α tnfr immune-mediated diseases therapeutic Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	pgrn tnf-α tnfr immune-mediated diseases therapeutic Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Lan YJ Sam NB Cheng MH Pan HF Gao J Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
description	Yue-Jiao Lan,1,2 Napoleon Bellua Sam,3 Ming-Han Cheng,1 Hai-Feng Pan,4,5 Jian Gao1 1Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 3Department of Medical Research and Innovation, School of Medicine, University for Development Studies, Tamale, Ghana; 4Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, People’s Republic of China; 5Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, People’s Republic of ChinaCorrespondence: Jian GaoPediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, People’s Republic of ChinaEmail gaojian@scmc.com.cn; gaojianayfy@163.comHai-Feng PanDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, People’s Republic of ChinaEmail panhaifeng@ahmu.edu.cnAbstract: Progranulin (PGRN), a secretory glycoprotein consisting of 593 amino acid residues, is a key actor and regulator of multiple system functions such as innate immune response and inflammation, as well as tissue regeneration. Recently, there is emerging evidence that PGRN is protective in the development of a variety of immune-mediated diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) by regulating signaling pathways known to be critical for immunology, particularly the tumor necrosis factor alpha/TNF receptor (TNF-α/TNFR) signaling pathway. Whereas, the role of PGRN in psoriasis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) is controversial. This review summarizes the immunological functions of PGRN and its role in the pathogenesis of several immune-mediated diseases, in order to provide new ideas for developing therapeutic strategies for these diseases.Keywords: PGRN, TNF-α, TNFR, immune-mediated diseases, therapeutic
format	article
author	Lan YJ Sam NB Cheng MH Pan HF Gao J
author_facet	Lan YJ Sam NB Cheng MH Pan HF Gao J
author_sort	Lan YJ
title	Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
title_short	Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
title_full	Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
title_fullStr	Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
title_full_unstemmed	Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
title_sort	progranulin as a potential therapeutic target in immune-mediated diseases
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/94ca2290387d4d6ab0fb7434aed4b006
work_keys_str_mv	AT lanyj progranulinasapotentialtherapeutictargetinimmunemediateddiseases AT samnb progranulinasapotentialtherapeutictargetinimmunemediateddiseases AT chengmh progranulinasapotentialtherapeutictargetinimmunemediateddiseases AT panhf progranulinasapotentialtherapeutictargetinimmunemediateddiseases AT gaoj progranulinasapotentialtherapeutictargetinimmunemediateddiseases
_version_	1718371135351947264

Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases

Ejemplares similares